Literature DB >> 18256842

[Intravitreal injection. Monitoring to avoid postoperative complications].

C H Meyer1, F Ziemssen, H Heimann.   

Abstract

Intravitreal injection is generally regarded as safe. Many of the potential complications caused by this procedure are extremely rare and can be avoided by careful inspection beforehand and proper performance of the injection. In rare cases, however, the administered drugs may cause various pharmacological side effects. This article summarizes the safety profiles of Macugen and Lucentis from the drug approval studies and describes initial findings on possible or observed side effects after intravitreal administration of Avastin. In addition, important points to observe in order to avoid intra- and postoperative complications are provided.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256842     DOI: 10.1007/s00347-008-1701-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  68 in total

1.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

2.  Effects of bevacizumab on retinal function in isolated vertebrate retina.

Authors:  M Lüke; M Warga; F Ziemssen; F Gelisken; S Grisanti; T Schneider; C Lüke; M Partsch; K U Bartz-Schmidt; P Szurman
Journal:  Br J Ophthalmol       Date:  2006-06-05       Impact factor: 4.638

3.  [Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection].

Authors:  M C Dwinger; I Pieper-Bodeewes; N Eter; F G Holz
Journal:  Klin Monbl Augenheilkd       Date:  2005-08       Impact factor: 0.700

4.  Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection.

Authors:  F B Aggio; M E Farah; G B de Melo; P A d'Azevedo; A C C Pignatari; A L Höfling-Lima
Journal:  Eye (Lond)       Date:  2007-02-02       Impact factor: 3.775

5.  Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.

Authors:  Donald J D'Amico; H N Masonson; Manju Patel; A P Adamis; E T Cunningham; D R Guyer; B Katz
Journal:  Ophthalmology       Date:  2006-04-27       Impact factor: 12.079

6.  Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  Ryan M Rich; Philip J Rosenfeld; Carmen A Puliafito; Sander R Dubovy; Janet L Davis; Harry W Flynn; Serafin Gonzalez; William J Feuer; Richard C Lin; Geeta A Lalwani; Jackie K Nguyen; Gaurav Kumar
Journal:  Retina       Date:  2006 May-Jun       Impact factor: 4.256

7.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.

Authors:  Andrew A Moshfeghi; Philip J Rosenfeld; Carmen A Puliafito; Stephan Michels; Erin N Marcus; Joshua D Lenchus; Anna S Venkatraman
Journal:  Ophthalmology       Date:  2006-10-05       Impact factor: 12.079

8.  [Preoperative infection prophylaxis with 1% polyvidon-iodine solution based on the example of conjunctival staphylococci].

Authors:  C A Binder; H Miño de Kaspar; V Klauss; A Kampik
Journal:  Ophthalmologe       Date:  1999-10       Impact factor: 1.059

9.  Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.

Authors:  C H Meyer; S Mennel; J C Schmidt; P Kroll
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

10.  [Intravitreal triamcinolone acetonide Complication of infectious and sterile endophthalmitis].

Authors:  I Kreissig; R F Degenring; J B Jonas
Journal:  Ophthalmologe       Date:  2006-01       Impact factor: 1.059

View more
  2 in total

1.  [Retinochoroidopathy after intravitreal anti-VEGF treatment].

Authors:  M Maier; N Feucht; I Lanzl; P Kook; C P Lohmann
Journal:  Ophthalmologe       Date:  2009-08       Impact factor: 1.059

2.  Ability of Mn(2+) to Permeate the Eye and Availability of Manganese-enhanced Magnetic Resonance Imaging for Visual Pathway Imaging via Topical Administration.

Authors:  Yao Chen; Chun-Yan Shi; Ying Li; Yun-Tao Hu; Hong-Bin Han; Xiao-Dong Sun; Satyajeet S Salvi; Zhi-Zhong Ma
Journal:  Chin Med J (Engl)       Date:  2016-08-05       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.